NFKB1 and renal carcinoma: Based on our experimental findings, we have conjectured that the downregulation of CYP51A1 in renal cancer tissues triggers an escalation in endogenous cholesterol biosynthesis through the NF-κB signaling pathway, thereby instigating tumor progression.